Cargando…

Immune oncology, immune responsiveness and the theory of everything

Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvi...

Descripción completa

Detalles Bibliográficos
Autores principales: Turan, Tolga, Kannan, Deepti, Patel, Maulik, Matthew Barnes, J., Tanlimco, Sonia G., Lu, Rongze, Halliwill, Kyle, Kongpachith, Sarah, Kline, Douglas E., Hendrickx, Wouter, Cesano, Alessandra, Butterfield, Lisa H., Kaufman, Howard L., Hudson, Thomas J., Bedognetti, Davide, Marincola, Francesco, Samayoa, Josue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989400/
https://www.ncbi.nlm.nih.gov/pubmed/29871670
http://dx.doi.org/10.1186/s40425-018-0355-5
_version_ 1783329454511095808
author Turan, Tolga
Kannan, Deepti
Patel, Maulik
Matthew Barnes, J.
Tanlimco, Sonia G.
Lu, Rongze
Halliwill, Kyle
Kongpachith, Sarah
Kline, Douglas E.
Hendrickx, Wouter
Cesano, Alessandra
Butterfield, Lisa H.
Kaufman, Howard L.
Hudson, Thomas J.
Bedognetti, Davide
Marincola, Francesco
Samayoa, Josue
author_facet Turan, Tolga
Kannan, Deepti
Patel, Maulik
Matthew Barnes, J.
Tanlimco, Sonia G.
Lu, Rongze
Halliwill, Kyle
Kongpachith, Sarah
Kline, Douglas E.
Hendrickx, Wouter
Cesano, Alessandra
Butterfield, Lisa H.
Kaufman, Howard L.
Hudson, Thomas J.
Bedognetti, Davide
Marincola, Francesco
Samayoa, Josue
author_sort Turan, Tolga
collection PubMed
description Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvironment: immune-active, immune-deserted and immune-excluded. This trichotomy is observable across most solid tumors (although the frequency of each landscape varies depending on tumor tissue of origin) and is associated with cancer prognosis and response to checkpoint inhibitor therapy (CIT). Various gene signatures (e.g. Immunological Constant of Rejection - ICR and Tumor Inflammation Signature - TIS) that delineate these landscapes have been described by different groups. In an effort to explain the mechanisms of cancer immune responsiveness or resistance to CIT, several models have been proposed that are loosely associated with the three landscapes. Here, we propose a strategy to integrate compelling data from various paradigms into a “Theory of Everything”. Founded upon this unified theory, we also propose the creation of a task force led by the Society for Immunotherapy of Cancer (SITC) aimed at systematically addressing salient questions relevant to cancer immune responsiveness and immune evasion. This multidisciplinary effort will encompass aspects of genetics, tumor cell biology, and immunology that are pertinent to the understanding of this multifaceted problem. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-018-0355-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5989400
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59894002018-06-20 Immune oncology, immune responsiveness and the theory of everything Turan, Tolga Kannan, Deepti Patel, Maulik Matthew Barnes, J. Tanlimco, Sonia G. Lu, Rongze Halliwill, Kyle Kongpachith, Sarah Kline, Douglas E. Hendrickx, Wouter Cesano, Alessandra Butterfield, Lisa H. Kaufman, Howard L. Hudson, Thomas J. Bedognetti, Davide Marincola, Francesco Samayoa, Josue J Immunother Cancer Hypothesis Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvironment: immune-active, immune-deserted and immune-excluded. This trichotomy is observable across most solid tumors (although the frequency of each landscape varies depending on tumor tissue of origin) and is associated with cancer prognosis and response to checkpoint inhibitor therapy (CIT). Various gene signatures (e.g. Immunological Constant of Rejection - ICR and Tumor Inflammation Signature - TIS) that delineate these landscapes have been described by different groups. In an effort to explain the mechanisms of cancer immune responsiveness or resistance to CIT, several models have been proposed that are loosely associated with the three landscapes. Here, we propose a strategy to integrate compelling data from various paradigms into a “Theory of Everything”. Founded upon this unified theory, we also propose the creation of a task force led by the Society for Immunotherapy of Cancer (SITC) aimed at systematically addressing salient questions relevant to cancer immune responsiveness and immune evasion. This multidisciplinary effort will encompass aspects of genetics, tumor cell biology, and immunology that are pertinent to the understanding of this multifaceted problem. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-018-0355-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-05 /pmc/articles/PMC5989400/ /pubmed/29871670 http://dx.doi.org/10.1186/s40425-018-0355-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Hypothesis
Turan, Tolga
Kannan, Deepti
Patel, Maulik
Matthew Barnes, J.
Tanlimco, Sonia G.
Lu, Rongze
Halliwill, Kyle
Kongpachith, Sarah
Kline, Douglas E.
Hendrickx, Wouter
Cesano, Alessandra
Butterfield, Lisa H.
Kaufman, Howard L.
Hudson, Thomas J.
Bedognetti, Davide
Marincola, Francesco
Samayoa, Josue
Immune oncology, immune responsiveness and the theory of everything
title Immune oncology, immune responsiveness and the theory of everything
title_full Immune oncology, immune responsiveness and the theory of everything
title_fullStr Immune oncology, immune responsiveness and the theory of everything
title_full_unstemmed Immune oncology, immune responsiveness and the theory of everything
title_short Immune oncology, immune responsiveness and the theory of everything
title_sort immune oncology, immune responsiveness and the theory of everything
topic Hypothesis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989400/
https://www.ncbi.nlm.nih.gov/pubmed/29871670
http://dx.doi.org/10.1186/s40425-018-0355-5
work_keys_str_mv AT turantolga immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT kannandeepti immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT patelmaulik immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT matthewbarnesj immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT tanlimcosoniag immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT lurongze immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT halliwillkyle immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT kongpachithsarah immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT klinedouglase immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT hendrickxwouter immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT cesanoalessandra immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT butterfieldlisah immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT kaufmanhowardl immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT hudsonthomasj immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT bedognettidavide immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT marincolafrancesco immuneoncologyimmuneresponsivenessandthetheoryofeverything
AT samayoajosue immuneoncologyimmuneresponsivenessandthetheoryofeverything